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We show that knockdown of 6-phosphogluconate dehydrogenase (6PGD) of the pentose phosphate
pathway (PPP) inhibits growth of lung cancer cells by senescence induction. This inhibition is not
due to a defect in the oxidative PPP per se. NADPH and ribose phosphate production are normal
in 6PGD knockdown cells and shutdown of PPP by knockdown of glucose-6-phosphate dehydroge-
nase (G6PD) has little effect on cell growth. Moreover, 6PGD knockdown cells can proliferate when
the PPP is bypassed by using fructose instead of glucose in medium. Signiﬁcantly, G6PD knockdown
rescues proliferation of cells lacking 6PGD, suggesting an accumulation of growth inhibitory glucose
metabolics in cells lacking 6PGD. Therefore, 6PGD inhibition may provide a novel strategy to treat
glycolyic tumors such as lung cancer.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Many tumors have enhanced glycolysis and a decrease in
mitochondrial oxidative phosphorylation [Supplementary data
(SI) Fig. 1]. Glucose can be taken up 15 times higher in cancer
compared to adjacent normal tissues [1]. Thus, a strategy to target
tumors by exploiting their high glucose uptake may offer high
intrinsic speciﬁcity.
The pentose phosphate pathway (PPP) is also known to be
hyperactive in cancer [2]. Flux measurements showed that PPP
can be elevated by almost 8 fold in breast cancer cells compared
to normal mammary epithelial cells [3]. The PPP consists of an
oxidative and a non-oxidative branches. While the importance of
the non-oxidative branch in tumor progression has been character-
ized at the steps catalyzed by transketolases [4,5], the potential
beneﬁcial role of the oxidative branch in cancer has received less
attention.
The oxidative branch of PPP is a major source of NAPDH impor-
tant in REDOX balance and biomolecule synthesis. Knockdown
G6PD, the ﬁrst enzyme of the PPP, sensitizes cancer cells to oxida-
tive stress induced by chemical agents or radiotherapy. However,
knockdown of G6PD alone without exogenous oxidative stresschemical Societies. Published by E
rogenase; G6PD, glucose-6-
athway
n).had only marginal effects in cancer growth in vitro [6,7]. Genetic
deletion experiments also showed that G6PD was not necessary
in pentose phosphate synthesis or proliferation but was only cru-
cial in protection against oxidative stress in mouse embryonic
stem cells [8,9].
Here, we probed the role of 6PGD, the third enzyme in the PPP,
in non-small cell lung carcinoma (NSCLC). Our results indicate that
PPP inhibition at the 6PGD juncture does not alter the steady-state
level of NADPH but yet dramatically inhibits tumor growth by a
senescence-associated mechanism. Unexpectedly, knockdown of
6PGD appears to cause cancer cells to metabolize glucose in such
a way that causes growth inhibition. Therefore, 6PGD may be a no-
vel and attractive target in the treatment of NSCLC and in other
glycolytic tumors.
2. Materials and methods
2.1. Cell culture
H1650 (ATCC) and H1975 (a gift from Dr. Susumu Kobayashi at
BIDMC) were grown in RPMI supplemented with 10% fetal bovine
serum (FBS). H1650 cells are bronchioalveolar carcinoma cells
carrying an activating EGFR mutation caused by a deletion in exon
19 (delE746-A750) and are geﬁtinib-sensitive. H1975 cells are lung
adenocarcinoma cells harboring twomutations in the EGFR (L858R/
T790M) and are geﬁtinib-insensitive. Coding regions of three
shRNAmir GIPZ-constructs against human 6PGD (V3LHS_381993;lsevier B.V. All rights reserved.
2390 V.P. Sukhatme, B. Chan / FEBS Letters 586 (2012) 2389–2395V3LHS_381995; and V3LHS_381996) from OpenBiosystems were
excised and sub-cloned into pTRIPZ vector for doxycycline inducible
expression. Lentivirus production and infection were done accord-
ing to themanufacturer’s protocol. Transduced cloneswere selected
in pools in puromycin (0.5 and 2 lg/ml for H1975 and H1650,
respectively). siRNAs against G6PD were purchased from Origene.
Transfection of siRNAs was performed as described previously
[10]. Under these conditions, expression knockdown should last
for at least 3 days per siRNA transfection. Coding region of mouse
6PGDwas ampliﬁed frommouse kidney cDNAs and sub-cloned into
pLNCX2 vector. Subsequent retrovirus production and transduction
ofH1975 cellswere performed as previously described [11]. Positive
clones were selected in pools in 0.8 lg/ml G418.
2.2. Proliferation assays
200,000 cells were seeded in a 10-cm plate in the presence of
2 lg/ml doxycycline for four days. Cells were then harvested and
seeded into 6-well plates at 50,000 cells/well in the presence of
2 lg/ml doxycycline and 10% FBS. Cells were grown with daily
changes of medium for four days and were then trysinized and
counted.
Alternatively, after doxycycline treatment for four days, 2000
cells were seeded in one well of a 96-well plate in the presence
of 2 lg/ml doxycycline and 10% FBS. Cells were grown with daily
changes of medium for four days. The culture plate was washed
extensively with PBS four times. Two hundred microliter of RIPI
buffer were added to each well, followed by agitation in a micro-
plate shaker for 20 min. One hundred microliters of 1 BCA protein
assay solution (BioRad) were added. After 10 min of incubation at
37 C, absorbance at 562 nm was measured to determine relative
protein level in each sample.
DNA synthesis was determined by Click-iT EdU Flow Cytome-
try Assay Kit from Invitrogen according to the manufacturer’s pro-
tocol. The principle is similar to the antibody-based detection of
bromo-deoxyuridine (BrdU) incorporation into DNA. Brieﬂy,
H1975 cells were treated with 2 lg/ml doxycycline for 6 days. Cells
were trypsinized and seeded in a 6-well plate (300,000 cells). Next
day, cells were incubated with 10 lM of nucleoside analog 5-ethy-
nyl-20deoxyuridine (EdU) in full medium for two hours. After
washing and ﬁxation, incorporated EdU was labeled with Alexa
Fluor 488 azide in the provided reaction buffer for 30 min. Cells
were analyzed by FACs sorting.
To test the effect of fructose in cell growth, cells were grown in
2 g/L of fructose and 10% dialyzed FBS in glucose-free RPMI. Doxy-
cycline treatment was done as described above. Cells were then
seeded into 6-well plates in either 2 g/L of fructose or 2 g/L glucose
for four additional days. Cells grew slower in fructose medium
compared to in glucose medium (See text).
2.3. Western blots
Human lung cancer lysates were from Protein Biotechnologies
(Ramona, CA). Normal human lung lysates were from Abcam and
Imgenex. Two 6PGD antibodies were used in this study. A mouse
monoclonal IgG1 raised against recombinant human 6PGD was
from Santa Cruz (sc-100316). A rabbit polyclonal IgG raised against
a peptide derived from amino acids 461–475 of human PGD was
obtained from Sigma (SAB1100532). A rabbit polyclonal anti p53
antibody raised against human p53 was purchased from Cell Sig-
naling (9282S). A rabbit polyclonal anti G6PD antibody raised
against a peptide corresponding to the N-terminus of human
G6PD was purchased from Cell Signaling (8866S). A mouse mono-
clonal IgG1 raised against actin was from Abcam (ab3280). A rabbit
polyclonal antibody against human p21 (epitope mapped to the C
terminus) was obtained from Cell Signaling (2947S). To prepare forlysates, 300,000 cells were seeded into one well of a 6-well plate.
Next day, cells were directly lyzed with 300 ll of SDS–PAGE buffer.
Fifty microliters were used for each load.
2.4. Senescence and NADPH detection
Cell staining of b-GAL activity was performed using a kit from
Cell Signaling. Senescence-associated b-GAL activity in whole cell
lysates was measured as described by Kindell et. al., except 4-
nitrophenyl-b-D-fucopyranoside (Sigma) was used as a chromo-
genic substrate [12]. Results were normalized against control
shRNA sample, which was arbitrarily set to 1. Cellular NADPH
was determined by a kit from Abcam (ab65349) according to the
manufacturer’s protocol. Brieﬂy, H1975 cells were treated with
doxycycline for four days to suppress 6PGD expression. Cells were
trypsizined and counted. 2  105 cells were pelleted and lysed in
400 ll extraction buffer provided. Two hundred ll of this lysate
were heated at 60 C for 30 min to decompose NADP+. Under these
conditions NADPH remained intact, according to the manufacturer.
A portion of this heated-extract was used to determine NADPH
concentration. Another portion was used in protein concentration
determination for normalization.
2.5. Metabolomic analysis
Analysis was performed by the mass spectrometry core at BID-
MC. Sample preparation was done according to a procedure devel-
oped by the core. Brieﬂy, both control and 6PGD-shRNA-1 H1975
cells were grown in triplicate in 2 lg/ml doxycycline for 3 days.
Metabolites were methanol extracted from equal number of cells
for analysis. After obtaining the average numeric values of the
spectral intensities from the triplicate of each species, fold changes
were calculated, with a positive value representing an increase in
abundance after 6PGD knockdown. Statistical analysis was per-
formed using the web server Metaboanalyst at http://www.metab-
oanalyst.ca/MetaboAnalyst/faces/Home.jsp [13]. Peak intensities
from the metabolomic analysis were uploaded to the server and
analyzed by the Signiﬁcance Analysis of Microarray and Metabo-
lites (SAM) to generate a list of metabolites that were signiﬁcantly
affected by 6PGD knockdown.
2.6. Oxygen consumption
H1975 cells were treated with doxycycline for 4 days to sup-
press 6PGD expression. 50,000 cells were seeded into each well
of a 24-well assay plate (Seahorse Bioscience) and grown over-
night. Oxygen consumption was performed using the Extracellular
Flux Analyzer XF24 from Seahorse Bioscience according to the
manufacturer’s protocol. Oxygen consumption values were nor-
malized to cell numbers and reported in pmol/min/50,000 cells.
2.7. Xenograft experiments
Control, 6PGD-shRNA-1, and 6PGD-shRNA-2 H1975 cells were
treated with doxycycline 2 lg/ml for three days to suppress
6PGD expression. 7  106 cells were injected subcutaneously into
nude mice (CODE: 088; Charles River). Mice were provided with
drinking water containing 2 mg/ml doxycycline. Tumors were ex-
cised after 18 days and weighed.
2.8. Statistical analysis
Anova analyses followed by Turkey post hoc tests at 95% conﬁ-
dence interval were done using the program GraphPadPrism (La Jol-
la, CA), where indicated. Results are reported as mean ± standard
deviation.
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3.1. 6PGD is upregulated in lung cancer
We ﬁrst measured the expression level of 6PGD in multiple
commercially available human lung cancer samples against normal
lung tissue by western blot. As shown in Fig. 1, 6PGD expression
was upregulated in all seven lung cancer samples when compared
to the normal adult lung tissues. Therefore, 6PGD may play an
important role in lung cancer biology, and lung cancer cells may
be more sensitive to 6PGD inhibition compared to normal lung
tissues.
3.2. Knockdown of 6PGD inhibits proliferation of NSCLC in vitro
Next, we tested the functional role of 6PGD in NSCLC using
H1975 cells as our model system (Fig. 2A). We used an inducible
shRNA system to knock down 6PGD expression. All three non-
overlapping shRNAs signiﬁcantly reduced the expression of 6PGD
and substantially decreased cell proliferation. Next, we performed
expression rescue experiments (Fig. 2B). H1975 cells expressing
control shRNA or 6PGD shRNA1 were transduced by either empty-
or mouse-6PGD retrovirus. Western blot analysis conﬁrmed the
expression of mouse 6PGD in infected cells; importantly, 6PGD
shRNA1 retained its ability to suppress endogenous 6PGD expres-
sion upon doxycycline induction without affecting the expression
of mouse 6PGD. Overexpression of mouse 6PGD alone enhanced
H1975 cell growth. In the presence of overexpressed mouse
6PGD, cell proliferation was signiﬁcantly restored in cells with
endogenous 6PGD knocked down. Our result conﬁrmed that the
growth inhibition was due to 6PGD knockdown and not a non-spe-
ciﬁc artifact of the shRNA. Suppression of 6PGD also resulted in sig-
niﬁcant growth inhibition in another NSCLC line called H1650 (SI
Fig. 2A). In addition to manual cell counting, proliferation was also
evaluated by assays based on total protein level (SI Fig. 2B) and
incorporation of a nucleoside analog into DNA (SI Fig. 2C). Collec-
tively, our results suggest that 6PGD is indispensable in cell prolif-
eration in NSCLC.
3.3. Knockdown of 6PGD induces cellular senescence and upregulates
p53 expression
We noticed that the cells with 6PGD knocked down were en-
larged and ﬂattened–shapes characteristic of senescence. We
therefore stained the cells for senescence-associated beta galacto-
sidase (SA-b-GAL) activity. Because shRNA1 and shRNA2 had the
most dramatic effects on cell proliferation (Fig. 2A), we tested
these two shRNAs in these experiments. 6PGD knockdown signiﬁ-
cantly increased number of cells positive for SA-b-GAL staining
(Fig. 3A–C). A chromogenic assay also showed that cells with
6PGD knocked down had signiﬁcantly higher SA-b-GAL activityFig. 1. 6PGD is overexpressed in human lung cancer. Seven commercially available hu
expression by western blotting. All nine protein samples were loaded onto the same SD
samples was occupied by a molecular weight marker. Quantiﬁcation was done using th
western blots. The pathological information of the tumors was tabulated.in their lysates (Fig. 3D), which was completely suppressed when
mouse 6PGD was overexpressed (SI Fig. 3A–E). We also examined
the expression of p53, another marker for senescence. p53 expres-
sion was upregulated in 6PGD knockdown (Fig. 3E) and restored to
normal level when mouse 6PGD was overexpressed (SI Fig. 3F). In
addition, another senescence marker p21Waf1/Cip1/Sdi1 [14,15] was
also upregulated upon 6PGD knockdown (SI Fig. 3G). Therefore,
suppression of 6PGD induces cellular senescence in these cancer
cells.
3.4. Knockdown of G6PD only has minor effects on cell growth
The decrease in cell proliferation in 6PGD knockdown implies
that the oxidative branch of the PPP could be indispensable for
growth. However, several published reports suggest that knock-
down of G6PD, an enzyme upstream of 6PGD, has only marginal ef-
fects in cell growth in vitro [6–9]. To address this discrepancy, we
knocked down G6PD by transient siRNA transfection in H1975
cells. In contrast to 6PGD knockdown, G6PD knockdown resulted
in only minor inhibition of proliferation (Fig. 4). Therefore, the dra-
matic growth inhibition observed when 6PGD was knocked down
was not simply a result of PPP blockade.
3.5. Knockdown of 6PGD does not reduce cellular NADPH levels but
upregulates oxygen consumption
Next, we examined NADPH level and found that 6PGD knock-
down in H1975 did not cause a reduction in NADPH level
(Fig. 5A). Previously, Filosa et. al. also reported that shutting down
PPP in mouse embryonic ﬁbroblasts by means of G6PD gene dele-
tion also resulted in unchanged levels of NADPH and glutathione
[8]. Therefore, our results suggest that 6PGD affected proliferation
in these cells in an NADPH-independent manner.
We suspected that upon 6PGD knockdown, these cancer cells
might have maintained NADPH level by enhanced glutaminolysis,
another major mechanism for NADPH production. We therefore
examined the rate of oxygen consumption of these cells, as NAPDH
production via glutaminolysis requires oxygen. Knockdown of
6PGD caused a signiﬁcant increase in oxygen consumption rate
(OCR) (Fig. 5B). Moreover, the OCR value of cells with endogenous
6PGD knocked down was completely restored to baseline when
mouse 6PGD was exogenously expressed (SI Fig. 4). Collectively,
our results show that knockdown of 6PGD in H1975 causes an in-
crease in oxygen consumption, supporting that notion that gluta-
minolysis might have been used to generate cellular NADPH.
3.6. Changes in levels of metabolites upon 6PGD knockdown
Since expression suppression of 6PGD did not lower NADPH le-
vel, we next determined whether the levels of other key metabo-
lites were affected. Both control- and 6PGD-shRNA1-expressingman lung cancer samples and two normal lung samples were analyzed for 6PGD
S–PAGE gel for analysis. The gap between the normal lung samples and the tumor
e program Image J (available at http://rsbweb.nih.gov/ij/) and is shown below the
Fig. 2. 6PGD is required in cell proliferation. (A) H1975 cells were retrovirally transduced to inducibly express a control or 6PGD speciﬁc shRNA (three tested). Cells were
treated with doxycycline (2 lg/ml) for four days. Some of these cells were analyzed by western blots; and some cells were seeded (50,000 cells) into a well of a 6-well plate
and grown for another four days to ascertain the effects on proliferation. (B) The anti-proliferative effect of knockdown of endogenous 6PGD could be completely rescued by
stable overexpression of mouse 6PGD. The monoclonal antibody preferentially detected human 6PGD, while the polyclonal antibody preferentially detected overexpressed
mouse 6PGD due to high protein abundance. Experiments were done in triplicate and were repeated at least three times. Representative results are shown. Error bars
represent standard deviation. Anova (p = 0.001) with Turkey post hoc test with conﬁdence interval at 95%. ⁄Indicates the change is statistically signiﬁcant.
Fig. 3. Knockdown of 6PGD induces cellular senescence and p53 upregulation.
H1975 cells were treated with 2 lg/ml doxycycline for 5 days. Cells were either
stained for b-GAL activity (A–C) or lysed and used in a chromogenic b-GAL assay for
quantiﬁcation (D) according to a published procedure with slight modiﬁcations
(21). p53 expression was also determined by western blots (E). Experiments were
done in triplicate and were repeated at least three times. Representative results are
shown. Error bars represent standard deviation. Anova (p = 0.0002) with Turkey
post hoc test with conﬁdence interval at 95%. ⁄Indicates the change is statistically
signiﬁcant.
Fig. 4. Knockdown of G6PDminimally inhibits H1975 cell proliferation. H1975 cells
were transiently transfected with a control siRNA or siRNAs against G6PD on Day 1.
On day 3, cells were split and seeded at 50,000 cells/well of a 6-well plate (A). A
portion of cells was used in western blotting on day 4 (B). Another round of siRNA
transfection was performed on day 4. Cells were grown for another 3 days,
harvested, and counted. Experiments were done in triplicate and were repeated at
least three times. Representative results are shown. Error bars represent standard
deviation. Anova (p = 0.0166) with Turkey post hoc test with conﬁdence interval at
95%. ⁄Indicates the change is statistically signiﬁcant.
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olites were extracted for analysis by mass spectrometry. Peak
intensities from the metabolomic analysis were uploaded to the
server MetaboAnalyst and analyzed by the Signiﬁcance Analysis of
Microarray and Metabolites (SAM) to generate a list of metabolites
that were signiﬁcantly affected by 6PGD knockdown (SI. Fig. 5) as
previously described [13]. Results are summarized according to
metabolic pathways (Table 1). A schematic of these metabolic
changes is presented in SI Fig. 6.
Knockdown of 6PGD resulted in a signiﬁcant increase of metab-
olites in the oxidative branch of the PPP. Speciﬁcally, 6-phospho-D-
gluconate and D-glucono-d-lactone-6-phosphate levels were up by11- and 7.9-fold, respectively. Direct determination of the effects in
the non-oxidative branch was more difﬁcult, as levels of some key
intermediates such as xylulose-5-phosphate and D-sedo-heptu-
lose-7-phosphate were not determined in our mass spectrometric
analysis. However, there was no change in the level of total ribose
phosphates, downstream products of the non-oxidative PPP.
Importantly, levels of all the triphosphate nucleotides were essen-
tially unchanged. Therefore, the activity of the non-oxidative
branch of the PPP did not seem to have altered when 6PGD was
knocked down.
Glycolysis also appeared to be affected by 6PGD knockdown.
Both glucose-6-phosphate and fructose-6-phosphate levels were
increased, perhaps due to a blockade in the PPP. On the other hand,
levels of fructose-1,6-bisphosphate, dihydroxyacetone phosphate,
and glyceraldehyde-3-phosphate were all signiﬁcantly lowered.
We speculate that these intermediates were shunted to the non-
oxidative PPP via the transketolase reactions using glyceralde-
hyde-3-phosphate as the entry point. These transketolase reactions
would have compensated for the blockade at 6PGD and provided a
Fig. 5. 6PGD knockdown does not reduce cellular NADPH level but increases
oxygen consumption. (A) H1975 cells were treated with doxycycline (2 lg/ml) for
four days and used to determine cellular NADPH level. Anova p = 0.9912. (B) H1975
cells were treated with doxycycline (2 lg/ml) for four days and then seeded onto a
Seahorse assay plate overnight. Levels of oxygen consumption were determined the
next day. Oxygen consumption is expressed in pmol/min/50,000 cells. Experiments
were done in triplicate and were repeated two times. Representative results are
shown. Error bars represent standard deviation. Anova (p = 0.0001) with Turkey
post hoc test with conﬁdence interval at 95%. ⁄Indicates the change is statistically
signiﬁcant.
Table 1
6PGD knockdown induces metabolic changes. H1975 cells were treated with 2 lg/ml
doxycycline for 3 days and processed for metabolomic analysis. Fold change
represents the value of knockdown over that of the control. Statistically signiﬁcant
changes are identiﬁed in bold and italic.
Sample type Fold change
PPP
D-Glucono-d-lactone-6-phosphate 7.9
6-Phospho-D-gluconate 11.0
Ribose-phosphate 1.2
Glycolysis
Glucose-6-phosphate 1.8
Fructose-6-phosphate 1.4
Fructose-1,6-bisphosphate 4.6
Dihydroxyacetone-phosphate 5.9
D-Glyceraldehdye-3-phosphate 3.8
1,3-Diphopshateglycerate 0
3-Phosphoglycerate 2.1
Phosphoenolpyruvate 2.8
Pyruvate 1.3
Lactate 1.2
NTPs/dNTPs
UTP 1.2
GTP 1.5
CTP 1
ATP 1.2
dTTP 1.2
dGTP 1.2
dCTP 1
dATP 1.1
TCA
Acetyl-CoA 1.6
Oxaloacetate 1.1
Citrate 1.1
Isocitrate 1.1
a-Ketoglutarate 1.2
Succinate 1.3
Fumarate 1
Malate 1.3
Glutamine/Glutamate
Glutamine 1.1
Glutamate 1.1
REDOX
NADPH 1.1
NADP+ 1.3
NADH 1.5
NAD+ 1.2
Glutathione disulﬁde 1
Glutathione 1.3
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dNTP/NTP levels.
In contrast, the steady-state levels of metabolites in the TCA cy-
cle did not change much in 6PGD knockdown. Additionally, among
all the species related to cellular REDOX measured in our analysis,
only glutathione level appeared to be slightly lowered. In particular
NADPH level was also determined to be unchanged by 6PGD
knockdown, consistent with result obtained by the colorimetric as-
say (Fig. 5A).
3.7. Glucose is critical for the inhibition of proliferation of H1975 cells
when 6PGD expression is suppressed
Next, we tested whether the use of glucose or fructose in the
medium might inﬂuence the phenotype of 6PGD suppression.
Fructose can be used to generate glycolytic metabolites via differ-
ent pathways. For example, in the liver, fructose can be phosphor-
ylated by fructokinase to yield fructose-1-phosphate and
ultimately glyceraldehyde-3-phosphate to re-enter glycolysis
[16]. Fructose can also enter glycolysis when phosphorylated by
hexokinase to become fructose-6-phosphate [17]. We reasoned
that if H1975 could metabolize fructose by these mechanisms, cells
grown in fructose without glucose would likely be devoid of glu-
cose-6-phosphate, bypassing the oxidative branch of the PPP.
H1975 cells were treated with doxycycline to induce 6PGD
knockdown in 2 g/L fructose (no glucose) for four days and were
then tested in proliferation assays in either 2 g/L fructose or glu-
cose (Fig. 6A). The growth rate of H1975 in fructose was about a
third of that in glucose. Therefore, H1975 cells could use fructose,
although less efﬁciently than with glucose. Perhaps rate of uptake
of fructose in these cells is slower than that of glucose, causing this
decrease in growth. Another possibility can be that fructose con-
version to fructose-6-phosphate is not very efﬁcient in these cells.
As expected, in the presence of glucose, 6PGD knockdown sig-
niﬁcantly inhibited proliferation. In contrast, in the presence of
fructose, 6PGD knockdown no longer inhibited cell growth when
compared to the corresponding control. Similarly, relative senes-
cence-associated b-GAL activity was only elevated in cells lacking
6PGD grown in glucose but not fructose (Fig. 6B). These results
suggest that the mechanism by which 6PGD knockdown inhibited
proliferation and induced senescence is separate from the funda-
mental functions of the oxidative branch of the PPP. Moreover,
6PGD knockdown appeared to have ‘‘changed’’ the cells to respond
to glucose as a growth inhibitor. The precise mechanism isunknown at this point. But it is likely due to changes in metabolic
ﬂux in key pathways.
3.8. G6PD knockdown rescues proliferation of H1975 cells lacking
6PGD
The fructose-rescue experiment led us to hypothesize that accu-
mulation of oxidative PPP metabolites may be growth inhibitory. If
true, knockdown of G6PD in cells lacking 6PGD should prevent
accumulation of these metabolites and restore proliferation of
H1975 cells even in the absence of 6PGD. Indeed, transient knock-
down of G6PD by siRNAs signiﬁcantly rescued proliferation of cells
with 6PGD knocked down (Fig. 7). Thus, our results suggest that 6-
phospho-D-gluconate and D-glucono-d-lactone-6-phosphate may
be inhibitors of proliferation.
3.9. 6PGD knockdown suppresses tumor growth in mice
Next, we sought to test whether 6PGD knockdown would
inhibit tumor growth in a xenograft model. Control-shRNA-,
6PGD-shRNA1-, and 6PGD-shRNA2-H1975 cells were induced with
doxycycline in vitro for three days prior to subcutaneous injection
Fig. 6. 6PGD knockdown inhibits proliferation and induces senescence in the presence of glucose but not fructose. H1975 cells were treated with 2 lg/ml doxycycline in
glucose-free medium supplemented with 10% dialyzed FBS and 2 g/L fructose (fructose medium) for four days. One portion of cells was analyzed by western blot (C); and
another portion was reseeded (50,000 cells/ well of a 6-well plate) in the presence of 2 g/L fructose or glucose with 10% dialyzed FBS for an additional four days, at which point
cells were counted (proliferation) (A) and used in a colorimetric assay for b-GAL activity (senescence) (B). Experiments were done in triplicate and were repeated three times.
Representative results are shown. Error bars represent standard deviation. Anova (p = 0.0001) with Turkey post hoc test with conﬁdence interval at 95%. ⁄Indicates the change
is statistically signiﬁcant; # indicates the change is not statistically signiﬁcant.
Fig. 7. G6PD knockdown rescues proliferation of cells lacking 6PGD. On day 1,
H1975 cells were transfected with a control or a mixture of three G6PD-speciﬁc
siRNAs. On day 4, another round of control/G6PD siRNA transfection was
performed, and doxycycline treatment to suppress 6PGD began. On day 8, cells
were reseeded for proliferation. On day 9, a portion of the cells were lyzed for
western blotting. Cells seeded for proliferation received an additional round of
control/G6PD siRNA transfection to ensure sustained G6PD knockdown. On day 13,
cells were counted. Experiments were done in triplicate and were repeated three
times. Representative results are shown. Error bars represent standard deviation.
Anova (p = 0.0001) with Turkey post hoc test with conﬁdence interval at 95%.
⁄Indicates the change is statistically signiﬁcant.
Fig. 8. 6PGD knockdown inhibits tumor growth in mice. H1975 cells were treated
with 2 lg/ml doxycycline for three days and implanted subcutaneously into nude
mice fed with drinking water containing 2 mg/ml doxycycline. Tumors were
excised after 18 days and weighed. Error bars represent standard deviation. n = 5
per group. Anova (p = 0.004) with Turkey post hoc test with conﬁdence interval at
95%. ⁄Indicates the change is statistically signiﬁcant.
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drinking water. Tumors were excised after 18 days and weighed.
As shown in Fig. 8, knockdown of 6PGD by either shRNA signiﬁ-
cantly retarded tumor growth.
4. Discussion
In this paper, we have identiﬁed 6PGD as a novel metabolic tar-
get in NSCLC. 6PGD appears to be upregulated in commercially
available human lung tumor samples compared to normal lung tis-
sues. Furthermore. 6PGD knockdown inhibited proliferation of
lung cancer cells in vitro and in mice. The inhibition appeared to
be due to senescence, as evidenced by the upregulation of threewell known senescence markers, SA-b-GAL, p53, and p21 [18]. To
our knowledge, this is the ﬁrst report of a metabolic target whose
inhibition alone induces cellular senescence.
The anti-proliferative effect of 6PGD knockdown was not be-
cause of a functional defect in the PPP. First, the total level of
NADPH and all deoxy- or ribo-nucleotide triphosphates were min-
imally affected. Second, knockdown of G6PD, the ﬁrst enzyme in
the PPP, only had a minor effect in H1975 proliferation. Third, a
‘‘by-pass’’ of the oxidative branch of the PPP by using fructose in-
stead of glucose in the growth medium rescued the growth inhibi-
tion in 6PGD knockdown. Fourth, proliferation of cells lacking
6PGD was signiﬁcantly restored when G6PD was simultaneously
knocked down.
Our metabolomic study revealed that knockdown of 6PGD re-
sulted in signiﬁcant accumulation of 6-phospho-D-gluconate and
D-glucono-d-lactone-6-phosphate, metabolites upstream of 6PGD.
As the oxidative branch of the PPP was blocked, these tumor cells
must have relied on other pathways to maintain level of NADPH,
perhaps from enhanced glutaminolysis. Glutamate can be metabo-
lized in mitochondria to yield malate, which is a substrate for malic
V.P. Sukhatme, B. Chan / FEBS Letters 586 (2012) 2389–2395 2395enzyme to produce pyruvate and NADPH [19]. Conversion of gluta-
mate to malate in the mitochondria would also enhance oxidative
phosphorylation and therefore oxygen consumption. Indeed, we
detected an approximately 2-fold increase in rate of oxygen con-
sumption when 6PGD was knocked down.
In the absence of 6PGD, the tumor cellsmay also have resorted to
upregulated transketolase reactions to produce ribose phosphates.
Many tumors overexpress transketolase-like enzymes [4,5] to use
metabolites from glycolysis, namely glyceraldehyde-3-phosphate
and fructose-6-phosphate, to produce ribose phosphates. Indeed,
knockdown of 6PGD resulted in a signiﬁcant decrease in the levels
of glyceraldehyde-3-phosphate (down 3.8) and dihydroxyacetone
phosphate (down 5.9). Thesemetabolitesmight have been rapidly
used up by transketolase or transketolase-like reactions. This rapid
consumption also may have led to a decrease in the levels of
metabolites both upstream and downstream of glyceraldehyde-3-
phosphate: fructose-1,6-bisphosphate (down 4.6), 3-phospho-
glycerate (down 2.1), and phosphoenolpyruvate (down 2.8).
Interestingly, pyruvate level was unchanged, presumably due to
production of pyruvate bymalic enzyme in generating NADPH from
malate.
Based on our analyses, it appears that these cancer cells, in
response to 6PGD inhibition, attempt to maintain the levels of
NADPH and dNTPs/NTPs by re-orchestrating the interconnections
among glycolysis, the PPP, and glutaminolysis. We speculate that
although successful initially, the changes in these critical metabolic
pathways are ultimately too drastic, resulting in causing the cells
to respond to glucose as a growth inhibitor through a novel mech-
anism yet to be identiﬁed. Detailed metabolic ﬂux measurements
will be needed to delineate these changes.
Our results also lead us to speculate that some of the glucose
metabolites accumulated in 6PGD knockdown may be growth
inhibitory. Since G6PD knockdown rescues proliferation of H1975
cells lacking 6PGD, 6-phospho-D-gluconate and D-glucono-d-lac-
tone-6-phosphate may be the culprits. It is known that 6-phos-
pho-D-gluconate is an allosteric activator of 6PGD [20]. Since
6PGD is knocked down in our system, this effect becomes irrele-
vant. 6-phospho-D-gluconate has also been shown to activate he-
patic phosphofructokinase and pyruvate kinase to channel excess
glucose away from the PPP to the production of pyruvate for lipo-
genesis [21,22]. In H1975 cells with 6PGD knocked down, however,
we detected accumulation of fructose-6-phosphate and reduction
of fructose-1,6-bisphosphate level, suggesting an inhibition rather
than activation of phosphofructokinase. We also detected a de-
crease in phosphoenolpyruvate level when 6PGD was knocked
down, which may suggest activation of pyruvate kinase, although
a concomitant accumulation of pyruvate was not seen. Perhaps
glucose metabolism in cancer cells are different from that of
normal cells that these extrapolations do not always apply. Exper-
iments designed to test the inhibitory activity of these metabolites
from oxidative PPP are currently underway.Acknowledgements
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